Applications for the One Young World Lead2030 challenges are now open!
One Young World Lead2030 is the world’s largest prize fund for young leaders that have an impact on the Sustainable Development Goals. Driven by some of the world’s leading companies, the initiative finds, finances and accelerates the SDG solutions created by founders under 30. They are proudly launching their second round of challenges for Lead2030, the world’s largest prize fund for young leaders working to achieve Sustainable Development Goals (SDGs).
Eligibility Criteria :
Directed by young people
Founded by a person from 18 to 30 years old.
Aligned
Evidently aligned with the SDG4 challenge. See the “Challenge scheme”.
In focus
The well-structured time horizon identified the main stakeholders and beneficiaries and proposed reasonable and well thought out results.
Proven strategy
Easily available, in the implementation phase or past.
Create impact
The solutions must have a positive social impact, for example, generate employment, eradicate poverty or develop skills.
Measurable
The impacts of the solutions must have been measured properly and / or be measurable.
Financially viable
Must be able to achieve efficiency and survive on its own through the resources they generate and / or the investments and donations they attract.
Scalable
Potential to perform as well or better after expanding in scope or size and / or being transported to other regions.
Benefits :
- A grant of US $ 50,000 from AstraZeneca
12 months of mentoring from a team of AstraZeneca professionals. The mentoring team will work to accelerate your solution based on the needs of your initiative or organization, such as:
– Business strategy
– Best practices for data collection.
– Monitoring and evaluation
– Product design
Each Lead2030 challenge partner is forming a mentoring team to provide expert advice and guidance to accelerate their solutions and increase their impact.
The selected winners of the challenge will receive communications support from Activation Supporter, Porter Novelli.